Literature DB >> 2322591

Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids.

J Veldscholte1, M M Voorhorst-Ogink, J Bolt-de Vries, H C van Rooij, J Trapman, E Mulder.   

Abstract

UNLABELLED: LNCaP tumor cells, derived from a metastatic lesion of a human prostatic carcinoma, are androgen-sensitive in cell culture. Although increase in growth rate is observed with low doses of progestagens or estradiol, these cells contain exclusively androgen receptors. In the present study the binding affinity of different ligands for both non-DNA- and DNA-binding (transformed) forms of the androgen receptor were analyzed. The cytosolic (non-transformed) form of the receptor displayed an abnormal high affinity for progestagens and estradiol when compared with the cytosolic androgen receptor from other sources. Subsequently the non-transformed forms of the androgen receptor obtained from LNCaP cell nuclei was studied. A high binding affinity was found not only for dihydrotestosterone, but also for progesterone and the synthetic progestagen R5020 (relative binding affinity 42% and 10% of dihydrotestosterone). The binding characteristics of the transformed androgen receptor were examined in intact cells at 37 degrees C. LNCaP cells were compared in this respect with COS cells containing the cloned human androgen receptor, normal human skin fibroblasts and PC3 (prostate) and NHIK (cervix) human tumor cell lines. The affinity of the transformed androgen receptors for the progestagen R5020 in LNCaP cells was significantly higher than in the other cell systems, although the differences were less pronounced than for the non-transformed receptor form. IN
CONCLUSION: the LNCaP tumor cells contain an androgen receptor with an abnormal binding site. This might be due to a mutation and/or a post-transcriptional effect.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2322591     DOI: 10.1016/0167-4889(90)90075-o

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  28 in total

1.  Estrogen mitogenic action. III. is phenol red a "red herring"?

Authors:  J E Moreno-Cuevas; D A Sirbasku
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Jul-Aug       Impact factor: 2.416

2.  [Antihormonal therapy in prostate cancer : Side effects].

Authors:  C H Ohlmann; P Thelen
Journal:  Urologe A       Date:  2017-04       Impact factor: 0.639

3.  Steroid hormone induction and expression patterns of L-plastin in normal and carcinomatous prostate tissues.

Authors:  J Zheng; N Rudra-Ganguly; G J Miller; K A Moffatt; R J Cote; P Roy-Burman
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

4.  Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer.

Authors:  Akash K Kaushik; Shaiju K Vareed; Sumanta Basu; Vasanta Putluri; Nagireddy Putluri; Katrin Panzitt; Christine A Brennan; Arul M Chinnaiyan; Ismael A Vergara; Nicholas Erho; Nancy L Weigel; Nicholas Mitsiades; Ali Shojaie; Ganesh Palapattu; George Michailidis; Arun Sreekumar
Journal:  J Proteome Res       Date:  2013-12-31       Impact factor: 4.466

5.  From estrogen to androgen receptor: a new pathway for sex hormones in prostate.

Authors:  S Yeh; H Miyamoto; H Shima; C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

6.  Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells.

Authors:  Yu Zhang; Jing Ni; Edward M Messing; Eugene Chang; Chin-Rang Yang; Shuyuan Yeh
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

7.  Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells.

Authors:  Grant Buchanan; Eleanor F Need; Jeffrey M Barrett; Tina Bianco-Miotto; Vanessa C Thompson; Lisa M Butler; Villis R Marshall; Wayne D Tilley; Gerhard A Coetzee
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

8.  Effects of sex steroids on cell growth and C-myc oncogene expression in LN-CaP and DU-145 prostatic carcinoma cell lines.

Authors:  F K Asadi; R Sharifi
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

9.  Induction of cre recombinase activity using modified androgen receptor ligand binding domains: a sensitive assay for ligand-receptor interactions.

Authors:  Stanislaw J Kaczmarczyk; Jeffrey E Green
Journal:  Nucleic Acids Res       Date:  2003-08-01       Impact factor: 16.971

Review 10.  William L. McGuire Memorial Symposium. Drug resistance to tamoxifen during breast cancer therapy.

Authors:  D M Wolf; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.